influenza
virus
divid
subtyp
base
antigen
two
envelop
glycoprotein
hemagglutinin
ha
neuraminidas
na
date
ha
na
subtyp
found
wild
aquat
bird
natur
reservoir
influenza
virus
ha
subtyp
avian
influenza
virus
subtyp
known
becom
highli
pathogen
avian
influenza
hpai
virus
natur
condit
hpai
virus
caus
acut
system
diseas
poultri
mortal
rate
often
approach
avian
human
transmiss
hpai
virus
limit
hpai
virus
never
report
caus
lethal
infect
human
first
emerg
hpai
viru
southern
china
hpai
viru
circul
poultri
decad
sinc
reemerg
southern
china
caus
unpreced
outbreak
wild
bird
poultri
asia
middl
east
africa
hpai
viru
occasion
infect
human
high
case
mortal
rate
pose
signific
pandem
threat
sinc
laboratoryconfirm
human
case
hpai
viru
infect
report
countri
fatal
case
octob
fact
prior
emerg
swineorigin
pandem
viru
impact
anim
public
health
asian
origin
hpai
viru
led
predict
viru
subtyp
might
caus
next
pandem
sinc
ha
subtyp
distinct
virus
circul
human
popul
ie
subtyp
recent
year
passiv
immun
human
human
monoclon
antibodi
mab
specif
viral
protein
test
anim
model
clinic
trial
provid
evid
effect
mab
prophylaxi
treatment
infecti
diseas
inde
human
mab
specif
respiratori
syncyti
viru
f
protein
alreadi
approv
us
food
drug
administr
use
clinic
case
importantli
particular
attent
paid
antibodi
therapi
highli
lethal
diseas
rabi
sever
acut
respiratori
syndrom
hendra
nipah
ebola
virus
known
ha
respons
receptor
bind
fusion
viru
envelop
host
cell
membran
primari
target
neutral
antibodi
influenza
virus
sinc
antibodi
gener
play
major
role
protect
immun
influenza
viru
infect
antibodi
therapi
might
potenti
option
prevent
lethal
infect
human
hpai
viru
studi
genet
modifi
mous
mab
neutral
infect
hpai
virus
creat
humanmous
chimer
mab
aim
clinic
applic
evalu
protect
potenti
mous
nonhuman
primat
model
hpai
viru
infect
hpai
viru
strain
ahong
aviet
repositori
laboratori
propag
madindarbi
canin
kidney
mdck
cell
repositori
laboratori
store
use
belong
clade
phylogenet
tree
respect
mdck
cell
grown
eagl
minim
essenti
medium
supplement
calf
serum
experi
use
infecti
virus
perform
biosafeti
level
facil
hokkaido
univers
research
center
zoonosi
control
research
center
anim
life
scienc
shiga
univers
medic
scienc
mous
mab
gener
accord
standard
procedur
briefli
sixweekold
femal
balbc
mice
japan
slc
immun
intramuscularli
two
time
formalininactiv
purifi
virion
boost
intraperiton
spleen
cell
harvest
day
boost
fuse
myeloma
cell
accord
standard
procedur
hybridoma
screen
secret
haspecif
mab
enzymelink
immunosorb
assay
elisa
clone
limit
dilut
result
cell
clone
inocul
balbc
mice
intraperiton
produc
ascit
antibodi
purifi
ascit
use
affigel
protein
map
ii
kit
biorad
mous
mab
use
control
antibodi
gener
describ
previous
humanmous
chimer
mab
gener
purifi
cultur
supernat
describ
previous
briefli
total
rna
extract
mous
hybridoma
cell
produc
mab
variabl
heavi
lightchain
region
amplifi
rtpcr
primer
design
antibodi
pcr
product
clone
express
vector
stabl
cell
line
express
recombin
mab
obtain
transfect
cho
cell
invitrogen
carlsbad
ca
chimer
mab
specif
ebola
viru
glycoprotein
gener
control
mab
use
methodolog
humanmous
chimer
mab
purifi
cultur
supernat
use
rprotein
sepharos
fast
flow
ge
healthcar
endotrap
red
profo
ag
mab
puriti
endotoxin
level
euml
confirm
perform
sdspage
endospeci
kit
seikagaku
corpor
respect
serial
dilut
antibodi
mix
plaqu
form
unit
pfu
virus
h
room
temperatur
inocul
onto
mdck
cell
h
inoculum
remov
cell
overlaid
bactoagar
bd
eagl
minim
essenti
medium
mem
two
day
later
number
plaqu
count
percentag
plaqu
reduct
calcul
escap
mutant
select
cultur
mdck
cell
presenc
mab
serial
dilut
mix
purifi
mab
final
concentr
incub
h
mixtur
inocul
confluent
mdck
cell
tissu
cultur
plate
h
adsorpt
cell
overlaid
mem
contain
agar
mab
ascit
final
dilut
incub
day
eight
escap
mutant
purifi
singl
isol
plaqu
propag
mdck
cell
serumfre
mem
contain
trypsin
nucleotid
sequenc
ha
gene
parent
strain
escap
mutant
determin
deduc
amino
acid
sequenc
compar
among
virus
number
sixweekold
femal
balbc
mice
passiv
immun
intraperiton
inject
purifi
mab
hour
hour
hour
intranas
challeng
mous
lethal
dose
anesthesia
isofluran
control
group
administ
control
antibodi
mixtur
mab
phosphatebuff
salin
pb
anim
monitor
daili
weight
loss
clinic
sign
five
day
challeng
mice
euthan
obtain
lung
tissu
sampl
lung
homogen
wv
prepar
mem
centrifug
g
min
supernat
examin
viru
infect
viru
titer
measur
plaqu
assay
use
mdck
cell
anim
experi
conduct
strict
complianc
anim
husbandri
welfar
regul
food
pellet
clea
japan
provid
day
recoveri
anesthesia
drink
water
avail
ad
libitum
anim
singli
hous
cage
equip
bar
climb
puzzl
feeder
environment
enrich
control
condit
humid
temperatur
light
h
h
dark
cycl
light
five
sevenyearold
femal
cynomolgu
macaqu
macaca
fasciculari
philippin
ina
research
use
cynomolgu
macaqu
use
present
studi
healthi
adult
absenc
influenza
viru
npspecif
antibodi
sera
confirm
experi
use
antigenspecif
elisa
anigen
aiv
ab
elisa
anim
genet
current
circul
influenza
viru
three
week
viru
inocul
telemetri
probe
data
scienc
intern
implant
periton
caviti
macaqu
ketaminexylazin
anesthesia
follow
isofluran
inhal
monitor
bodi
temperatur
macaqu
use
studi
free
herp
b
viru
hepat
e
viru
mycobacterium
tuberculosi
shigella
spp
salmonella
spp
entamoeba
histolytica
individu
macaqu
distinguish
treatment
number
c
macaqu
inject
control
mab
macaqu
treat
mab
ic
immunosuppress
macaqu
inject
control
mab
immunosuppress
macaqu
treat
mab
icp
immunosuppress
macaqu
inject
mab
peramivir
itp
immunosuppress
macaqu
treat
mab
peramivir
macaqu
kg
inocul
day
total
ml
nasal
caviti
ml
nostril
tonsil
ml
tonsil
pipett
trachea
ml
cathet
ketaminexylazin
anesthesia
mab
control
mab
mixtur
mab
administ
intraven
twice
mgheaddos
mgkg
day
infect
anim
monitor
daili
approxim
everi
hour
clinic
score
tabl
serum
sampl
obtain
day
viru
titrat
cotton
stick
eiken
chemic
use
collect
fluid
sampl
nasal
caviti
trachea
ketaminexylazin
anesthesia
stick
subsequ
immers
ml
pb
contain
bovin
serum
albumin
bsa
antibiot
bronchoscop
machida
endoscop
cytolog
brush
olympu
use
obtain
bronchial
sampl
brush
immers
ml
pb
bsa
viral
titer
determin
tissu
cultur
infecti
dose
mdck
cell
immunosuppress
treatment
macaqu
cyclophosphamid
cp
nacalai
tesqu
cyclosporin
ca
novarti
pharma
use
cp
mgkg
administ
intraven
bolu
inject
day
ca
mgkg
administ
oral
stomach
use
cathet
day
day
confirm
treatment
cp
ca
decreas
number
white
blood
cell
macaqu
fig
experi
peramivir
hydrat
mgkgdose
provid
shionogi
co
ltd
administ
intraven
bolu
inject
day
day
day
infect
sinc
patient
sever
respiratori
ill
might
difficulti
intak
inhal
drug
chose
peramivir
hydrat
antivir
agent
intraven
inject
concentr
cytokin
sera
tissu
homogen
measur
use
milliplex
map
nonhuman
primat
cytokin
panel
luminex
millipor
although
experi
origin
design
collect
sampl
anim
virolog
immunolog
studi
termin
day
anim
euthan
clinic
score
reach
human
endpoint
subject
autopsi
collect
tissu
sampl
macaqu
unfortun
found
dead
interv
monitor
time
point
also
immedi
subject
autopsi
anim
ie
euthan
dead
count
nonsurvivor
autopsi
indic
day
viru
infect
lung
tissu
sampl
fix
formalin
embed
paraffin
section
stain
hematoxylin
eosin
h
e
influenza
viru
nucleoprotein
np
antigen
stain
antisera
rabbit
immun
np
synthet
peptid
aftgntegrtsdmr
posit
np
sequenc
genbank
access
number
treatment
pressur
cooker
citratephosph
buffer
incub
antirabbit
immunoglobulin
antibodi
conjug
horseradish
peroxidas
nichirei
bioscienc
inc
np
detect
diaminobenzidin
nichirei
bioscienc
inc
anim
studi
carri
strict
accord
guidelin
proper
conduct
anim
experi
scienc
council
japan
anim
experi
conduct
strict
complianc
anim
husbandri
welfar
regul
mous
studi
approv
hokkaido
univers
anim
care
use
committe
permit
number
nonhuman
primat
studi
also
carri
strict
accord
guidelin
husbandri
manag
laboratori
anim
research
center
anim
life
scienc
shiga
univers
medic
scienc
standard
relat
care
manag
etc
experiment
anim
notif
march
prime
minist
offic
japan
protocol
approv
shiga
univers
medic
scienc
anim
experi
committe
permit
number
procedur
perform
ketamin
xylazin
anesthesia
effort
made
minim
suffer
regular
veterinari
care
monitor
balanc
nutrit
environment
enrich
provid
research
center
anim
life
scienc
shiga
univers
medic
scienc
macaqu
euthan
endpoint
day
viru
inocul
immunolog
virolog
analysi
use
ketamin
xylazin
anesthesia
follow
intraven
inject
pentobarbit
mgkg
anim
monitor
twice
day
studi
clinic
score
shown
tabl
anim
would
euthan
clinic
score
reach
human
endpoint
mab
show
neutral
activ
fig
inhibitori
concentr
mab
respect
determin
epitop
mab
escap
mutant
select
presenc
mab
deduc
amino
acid
sequenc
parent
viru
mutant
compar
lysin
threonin
asparagin
glutam
acid
substitut
found
posit
clone
mutant
respect
mutant
substitut
lysin
glutam
acid
posit
data
shown
amino
acid
residu
posit
locat
near
receptorbind
site
antigen
site
ha
molecul
accordingli
mab
show
hemagglutinationinhibit
activ
data
shown
convert
mab
humanmous
chimer
mab
neutral
activ
analyz
vitro
fig
mab
significantli
reduc
infect
virus
dosedepend
manner
wherea
neg
control
mab
inhibitori
concentr
mab
respect
valu
similar
origin
mous
mab
indic
genet
modif
mab
significantli
affect
neutral
activ
vitro
next
investig
potenti
mab
protect
mice
infect
known
highli
virul
mice
mice
treat
antibodi
day
day
viru
challeng
lethal
dose
surviv
without
clinic
symptom
wherea
control
mice
die
euthan
within
day
challeng
fig
b
control
mice
uniformli
show
sever
weight
loss
data
shown
treatment
day
infect
also
partial
protect
mice
fig
although
surviv
mice
treat
show
moder
weight
loss
data
shown
control
mice
exhibit
sever
weight
loss
succumb
infect
consist
surviv
data
lung
viru
titer
mice
treat
ha
mab
day
viru
challeng
significantli
lower
mice
given
respect
control
antibodi
fig
statist
signific
treatment
infect
modestli
reduc
titer
fig
result
indic
mab
highli
protect
hpai
viru
mice
examin
therapeut
efficaci
mab
nonhuman
primat
model
hpai
viru
infect
use
sinc
viru
caus
sever
often
lethal
diseas
cynomolgu
macaqu
macaqu
infect
day
treat
mab
control
mab
twice
day
infect
bodi
temperatur
rose
upon
infect
decreas
first
inject
mab
rose
day
fig
one
three
macaqu
inject
control
mab
die
day
wherea
three
macaqu
treat
mab
surviv
day
infect
tabl
exp
viral
titer
nasal
tracheal
bronchial
sampl
macaqu
treat
mab
lower
macaqu
inject
control
mab
first
inject
mab
ie
day
fig
one
mab
macaqu
viru
slightli
detect
nasal
bronchial
sampl
day
fig
c
although
viru
recov
nasal
sampl
treat
macaqu
titer
lower
macaqu
inject
control
mab
fig
infecti
virus
recov
lung
macaqu
even
day
tabl
interestingli
viral
titer
nasal
tracheal
bronchial
sampl
drastic
increas
day
one
macaqu
treat
mab
fig
similar
phenomenon
partial
observ
treat
macaqu
viral
titer
tracheal
bronchial
sampl
often
higher
control
macaqu
day
fig
c
accordingli
rel
high
titer
viru
detect
lung
collect
day
tabl
two
treat
macaqu
lost
appetit
viru
infect
clinic
score
increas
tempor
recov
inject
mab
fig
result
indic
mab
reduc
viral
titer
respiratori
secret
treat
macaqu
although
inhibit
viral
propag
temporari
two
treat
macaqu
confirm
mab
concentr
day
challeng
maintain
treat
macaqu
day
fig
thu
examin
appear
escap
mutant
sequenc
viral
rna
extract
tracheal
sampl
collect
mab
macaqu
day
found
amino
acid
substitut
ident
seen
escap
mutant
select
vitro
ie
clone
viral
gene
obtain
respect
indic
viral
escap
occur
treatment
period
examin
protect
potenti
mab
use
immunocompromis
macaqu
model
influenza
viru
infect
macaqu
pretreat
cp
ca
infect
day
increas
bodi
temperatur
observ
infect
macaqu
fig
bodi
temperatur
rose
upon
infect
decreas
treatment
mab
rose
day
three
macaqu
inject
control
mab
succumb
infect
day
wherea
two
five
macaqu
inject
mab
also
die
day
respect
tabl
exp
infecti
virus
consist
detect
nasal
tracheal
bronchial
sampl
macaqu
inject
control
mab
death
fig
hand
viral
titer
nasal
sampl
tracheal
sampl
five
macaqu
treat
mab
decreas
day
ie
inject
antibodi
fig
b
also
note
viral
titer
bronchial
sampl
markedli
reduc
day
fig
howev
bronchial
sampl
titer
day
similar
control
macaqu
fig
clinic
score
improv
clinic
score
day
slightli
regain
appetit
mab
treatment
fig
viral
titer
increas
day
trachea
bronchial
sampl
treat
macaqu
eg
case
treatment
immunocompet
macaqu
furthermor
infecti
virus
detect
lobe
lung
viru
replic
lung
treat
macaqu
limit
day
tabl
virus
substitut
ha
recov
tracheal
sampl
clone
ha
gene
respect
wherea
concentr
mab
circul
serum
day
challeng
maintain
treat
macaqu
fig
result
indic
treatment
mab
result
reduc
viral
load
partial
protect
lethal
hpai
viru
infect
immunosuppress
macaqu
though
mab
treatment
might
select
escap
mutant
sinc
escap
mutant
frequent
select
macaqu
treat
mab
alon
examin
combin
therapi
mab
neuraminidas
inhibitor
peramivir
reduc
viral
replic
emerg
escap
mutant
cp
capretr
macaqu
infect
mab
inject
day
addit
continu
administr
peramivir
day
two
macaqu
treat
peramivir
alon
human
euthan
day
respect
wherea
one
macaqu
receiv
combin
treatment
also
die
day
tabl
exp
increas
bodi
temperatur
observ
two
control
one
macaqu
fig
viral
titer
nasal
tracheal
sampl
macaqu
treat
mab
peramivir
almost
undetect
day
fig
b
unlik
mab
treatment
alon
fig
increas
viral
titer
bodi
temperatur
observ
day
surviv
macaqu
treat
mab
togeth
peramivir
fig
fig
concentr
mab
serum
maintain
day
challeng
macaqu
fig
accordingli
infecti
virus
slightli
detect
limit
part
lung
macaqu
tabl
escap
mutat
ie
found
clone
viral
gene
obtain
mab
macaqu
along
reduc
viral
recoveri
sampl
clinic
score
gener
improv
day
result
indic
combin
therapi
mab
peramivir
inhibit
viral
propag
effici
mab
peramivir
treatment
alon
might
also
result
reduc
select
escap
mutant
improv
surviv
hpai
viru
infect
macaqu
determin
caus
death
macaqu
examin
inflamm
measur
product
sera
lung
tissu
immunocompet
macaqu
model
elev
level
observ
day
serum
one
macaqu
die
day
macaqu
fig
addit
lung
level
day
markedli
higher
macaqu
fig
immunocompromis
macaqu
model
mark
increas
detect
sera
andor
lung
tissu
macaqu
inject
control
mab
fig
g
similarli
increas
level
detect
mab
macaqu
die
day
bacteri
infect
detect
cerebr
ventricl
data
shown
rapid
respons
observ
suggest
macaqu
die
bacteri
mening
viru
infect
combin
therapi
experi
increas
level
detect
sera
human
euthan
die
infect
fig
level
lung
tissu
rel
high
fig
consist
human
case
previous
describ
result
suggest
increas
serum
lung
might
associ
system
inflammatori
respons
lead
death
increas
product
also
seen
macaqu
sever
diseas
cytokin
test
unlik
correl
diseas
sever
macaqu
fig
sinc
elev
level
like
involv
varieti
system
inflammatori
state
associ
endotheli
barrier
dysfunct
cytokin
could
import
mediat
increas
endotheli
permeabl
might
result
system
organ
failur
caus
hpai
viru
infect
evalu
progress
diseas
antibodi
treatment
examin
lung
patholog
macaqu
subject
autopsi
macroscop
dark
red
area
repres
inflamm
congest
larger
lung
control
immunocompet
macaqu
lung
two
immunocompet
macaqu
treat
mab
fig
dark
red
area
larger
lung
lung
find
concord
viru
titer
lung
collect
autopsi
tabl
immunosuppress
macaqu
treat
control
antibodi
macroscop
lesion
inflamm
hemorrhag
congest
lung
much
smaller
lung
immunocompet
macaqu
fig
immunosuppress
macaqu
treat
mab
reddish
lesion
smaller
control
macaqu
fig
particular
macroscop
inflamm
observ
around
central
bronchu
immunosuppress
macaqu
also
treat
peramivir
macroscop
reddish
lesion
smaller
immunocompet
immunosuppress
macaqu
treat
without
peramivir
fig
lung
die
day
viru
infect
dark
red
edemat
lesion
examin
histolog
chang
lung
collect
infect
macaqu
fig
sever
pneumonia
reduc
air
space
seen
control
immunocompet
macaqu
macaqu
treat
mab
fig
b
high
magnif
imag
lymphoid
neutrophil
infiltr
thicken
alveolar
wall
alveolar
edema
observ
fig
macaqu
euthan
day
show
similar
histolog
chang
data
shown
immunohistochem
stain
influenza
viru
antigen
npposit
cell
wide
distribut
accumul
focal
lung
control
macaqu
day
viru
infect
fig
contrast
npposit
cell
seen
accumul
mab
macaqu
fig
reduc
number
npposit
cell
also
seen
lung
treat
macaqu
data
shown
macaqu
immunosuppress
condit
lymphoid
infiltr
mild
compar
immunocompet
macaqu
lung
tissu
obtain
control
macaqu
day
viru
infect
pulmonari
edema
seen
alveoli
result
loss
air
space
fig
c
macaqu
treat
mab
air
space
decreas
alveolar
septa
thicken
part
air
content
still
preserv
fig
npposit
cell
seen
alveolar
epithelium
control
macaqu
frequent
mab
macaqu
fig
f
cuboid
epitheli
cell
posit
np
antigen
type
ii
alveolar
epitheli
cell
less
sever
histolog
chang
viru
infect
also
seen
treat
macaqu
compar
control
macaqu
data
shown
differ
histolog
chang
frequenc
npposit
cell
control
mab
macaqu
also
seen
macaqu
treat
togeth
peramivir
fig
current
strategi
control
influenza
includ
vaccin
antivir
drug
treatment
neuraminidas
inhibitor
use
hpai
viru
infect
human
well
season
influenza
caus
virus
ha
subtyp
howev
efficaci
neuraminidas
inhibitor
human
infect
unclear
due
inevit
lack
adequ
control
studi
moreov
drugresist
virus
inde
detect
patient
importantli
virus
reduc
sensit
neuraminidas
inhibitor
also
isol
chicken
endem
area
thu
altern
strategi
prophylaxi
treatment
need
develop
pandem
prepared
influenza
viru
passiv
transfer
neutral
antibodi
may
provid
altern
strategi
prophylaxi
treatment
pandem
influenza
report
hpai
virusinfect
patient
recov
treatment
convalesc
plasma
suggest
passiv
immunotherapi
may
promis
option
treatment
hpai
viru
infect
efficaci
mous
mab
specif
evalu
mous
model
promis
result
treatment
prophylaxi
howev
clinic
use
induct
antimous
mabspecif
antibodi
respons
reduc
neutral
capac
given
mab
also
limit
repeat
use
mous
antibodi
thu
passiv
immunotherapi
human
human
mab
also
test
mous
ferret
model
nevertheless
protect
potenti
mab
remain
elucid
nonhuman
primat
model
hpai
viru
infect
help
develop
clinic
antibodi
therapi
also
gener
humanmous
chimer
monoclon
antibodi
mab
show
strong
neutral
activ
hpai
virus
isol
human
evalu
protect
potenti
anim
model
particular
use
cynomolgu
macaqu
model
simul
hpai
viru
infect
human
faith
thu
use
anim
model
vaccin
pathogenesi
studi
influenza
viru
infect
found
treatment
mab
reduc
viral
load
partial
protect
macaqu
lethal
infect
hpai
viru
noteworthi
protect
effect
promin
immunosuppress
macaqu
might
provid
model
protect
sever
clinic
diseas
immunocompromis
patient
thu
proof
concept
studi
provid
first
evid
antibodi
therapi
may
benefici
effect
clinic
case
hpai
viru
infect
human
importantli
howev
mutant
virus
escap
neutral
mab
recov
macaqu
treat
mab
alon
becam
predomin
day
infect
wherea
reduc
viru
replic
upon
treatment
mab
observ
treat
macaqu
initi
phase
infect
result
suggest
shown
mous
model
hpai
viru
infect
combin
therapi
use
two
differ
mab
might
need
prevent
gener
escap
mutant
would
like
benefici
taken
togeth
result
obtain
present
studi
demonstr
therapeut
use
neutral
mab
result
reduc
viral
load
improv
protect
nonhuman
primat
model
lethal
viru
infect
addit
also
shown
combin
therapi
antivir
drug
provid
better
protect
reduc
emerg
escap
mutant
combin
therapi
antibodi
recogn
differ
epitop
may
also
attenu
symptom
prevent
select
escap
mutant
